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Abstract
Background—Children with chronic diseases are at risk for low bone mineral density (BMD). 
There are no studies of BMD in children with congenital heart disease and particularly SV. 
Children with this defect are often treated with warfarin, suspected to negatively impact BMD in 
adults. We assessed BMD in patients with single ventricle (SV) physiology and compared the 
BMD of subjects taking warfarin to those who were not.
Methods—Subjects 5-12 years with SV were included. BMD z-scores by dual-energy X-ray 
absorptiometry (DXA) of the spine and total body less head (TBLH) were obtained. Calcium 
intake, activity level, height, and Tanner stage were assessed. Linear regression models and t-tests 
were used to investigate differences between participants and normative data as well as between 
subjects' subgroups.
Results—Twenty six subjects were included; 16 took warfarin. Mean BMD z-score at the spine 
was significantly lower than expected at -1.0±0.2 (p<0.0001), as was the BMD z-score for TBLH 
at - 0.8±0.2 (p<0.0001). Those results remained significant after adjusting for height. Subjects 
who were on warfarin tended to have lower BMD at both the spine and TBLH than those who 
were not, with a z-score difference of 0.6±0.46 at the spine (p=0.106) and a difference of 0.4±0.34 
at TBLH (p=0.132).
Conclusions—BMD is significantly reduced in children with SV. Warfarin appears to lower 
BMD but the effect is less conclusive. Continued evaluation is recommended for these patients at 
risk for reduced bone density. Evaluation of other cardiac patients on warfarin therapy should also 
be considered.
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Introduction
Since inception of the Fontan procedure in 1971 to treat single ventricle patients,[1] early 
mortality has decreased substantially, and delineating and avoiding associated long-term 
morbidities have become of great interest. Described morbidities include dysrhythmia, 
systemic ventricular dysfunction, protein-losing enteropathy, and thromboembolic 
complications.[2-4] With increasing number of patients surviving the Fontan operation well 
into adulthood anthropometric patterns have been well described in such patients.[5-8] 
However, no study has looked at the bone mineral density (BMD) in such a population 
although these patients are, theoretically, at a greater risk of having low BMD because of the 
chronicity of their condition.[9-10]
Thrombolic events (TE) in Fontan patients occur at the venous and arterial level. Venous TE 
have been described in 3 to 16% of patients post-Fontan, and arterial emboli occur in 3 to 
19% of patients.[11-17] However, the time course at which TE occur is not well elucidated: 
While some authors report TE most commonly in the first year with a second peak 10 years 
after surgery,[12] others observed the initial risk and a continued risk thereafter,[18] or no 
association with time after surgery.[11]
Because of the possibility of thrombosis, anticoagulation has been used for patients after 
Fontan completion. Retrospective studies have shown anticoagulation to reduce the risk of 
TE.[19-20] However, multiple other studies have found that prophylactic anticoagulation is 
not routinely required in all children after Fontan completion.[21-25] More recently, a 
multicenter prospective study in which patients post Fontan were randomized to receive 
warfarin or aspirin failed to show any difference between aspirin and warfarin as primary 
thromboprophylaxis in the first 2 years after Fontan surgery.[26] Hence, the necessity, 
optimal duration, and best means of anticoagulation for Fontan patients remain controversial 
leading to different practices among cardiologists ranging from no anticoagulation to 
chronic warfarin +/- aspirin treatment.[21-22]
Recently, there has been mounting concern that warfarin might worsen bone mineral accrual 
and maintenance and may lead to osteoporosis in adult.[27-30] There are only two published 
studies that examine the effect of warfarin in children.[31-32]
The aim of our study was, therefore, to describe results of BMD assessments performed on 
subjects with the same medical condition (SV) and within a narrow age range to study the 
effect of warfarin on BMD. We hypothesized that children with single ventricle (SV) 
physiology would have lower BMD compared to the normal population. We also 
hypothesized that, within our SV group, subjects who were on warfarin would have lower 
BMD compared to those who were not.
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Materials and Methods
We included children between 5 and 12 years of age with SV physiology, without known 
bone disease or oral steroid intake. By starting at age 5, we incorporated the lowest age for 
which normative densitometry data for BMD were available. By limiting the upper age to 12 
years, we tried to eliminate puberty as a confounding variable. There are also fewer 
discrepancies in diet and exercise within this age group.
Between March 2010 and March 2011, we enrolled patients satisfying our criteria. The 
project was approved by the Indiana University Institutional Review Board. Consent from 
parents or guardians as well as assent from children older than 7 years of age were obtained. 
Questionnaires to assess for calcium intake, physical activity, and Tanner staging were also 
completed.
BMD of the total body less head (TBLH), lumbar spine (L1-L4), and hip were assessed 
using dual energy x-ray absorptiometry (DXA) (Lunar Prodigy). Results were expressed as z 
scores based upon reference manufacturer data.
Calcium intake was assessed using a questionnaire based on the criteria by Musgrave et. al.
[33] The questionnaire allows estimations of calcium intake in mg/day. History of fractures 
in our cohort was obtained from a questionnaire that guardians filled out about their children 
prior to the DXA scan.
Physical activity was assessed using the Physical Activity Questionnaire for Older Children 
(PAQ-C).[34] This questionnaire measures general physical activity over the previous 7 
days. It consists of nine items; each has a 5-point response scale ranging from low “1” to 
high activity “5”. A total PAQ-C summary score, which can range from 1 (low activity) to 5 
(high-activity), is calculated by dividing the total scores for the nine items by the number of 
items. The Physical Activity Questionnaire has been shown to have acceptable validity for 
research purposes: one week test ± retest reliability was r = 0.75 for boys and 0.82 for girls.
[34] Tanner staging was self-reported by patients and their guardians.[35]
Clinical, surgical, catheterization and echocardiography data were collected on patients 
enrolled. Patients were considered to have been on long-term warfarin therapy if they had 
been prescribed the anticoagulant for longer than 18 months. Compliance was confirmed by 
reviewing the patients' international normalized ratio (INR) values. Except for the presence 
of a mechanical valve where a target INR of 2.5 and above was sought, an INR between 1.5 
and 2.5 is considered therapeutic in our SV patients.
Oxygen saturation data were collected from clinic notes; a cutoff of 92% for the oxygen 
saturation determined by pulse oximetry was selected to differentiate between patients with 
low and high saturation.
All analyses were performed using the standardized BMD measured from the spine, the 
standardized BMD for the TBLH, and the bone mineral content (BMC) which represents the 
bone mass. The one sample t tests were used to test for differences between the study 
participants and the normal population. To test for differences among patients who had 
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different functional SV and among those who were on warfarin, pooled t tests were used. 
Regression models were fit in order to investigate the difference among these patients while 
controlling for potential confounding variables. The response variable for these models was 
the standardized BMD or BMC while the main factor of interest was warfarin or functional 
single ventricle. Other covariates included in the models were Fontan type, activity level, 
oxygen saturation by pulse oximetry, and height. Results are given below and are reported as 
“mean ± standard error” along with a one-sided p-value. The one-sided p-value is reported 
since there is prior indication that those patients on warfarin and with single right ventricle 
were predisposed to having lower BMD.
Results
Seventy subjects were identified who fit our inclusion criteria. Thirty seven were contacted 
prior to their appointments. Of those, 9 patients refused enrollment and 2 had scheduling 
difficulties. The remaining 26 constituted our cohort. (Table 1)
Thirteen (50%) were male. All but three were white. Median age at time of the DXA was 8.6 
years (range 5.6 - 11.5). Median z-score for height was -1.08 (range -3.82 to 0.94). Median 
BMI z-score was -0.03 (range -2.96 to 1.83). All subjects were prepubertal except for one 
11.5 year old-girl, who was Tanner III. The calcium and activity questionnaire was 
completed by 24 participants. Median calcium intake was 1100 mg daily (range 360 – 2600) 
with 19 patients reporting intakes of more than 1000 mg/day. The median score on the PAQ-
C was 2.5 (1 – 4.1) indicating mild to moderate activity levels.
Four subjects reported a history of bone fracture. All of them were in the group receiving 
warfarin. Three were females and 1 was male. One subject had an arm broken at age 2 years; 
one had a thumb broken at age 2 years; one sustained a leg fracture as a baby, and the fourth 
one had both her elbows broken at age 8 years while playing soccer. The first three subjects 
sustained their fractures prior to the initiation of the warfarin therapy. The last subject had 
been on warfarin when her fracture occurred; the z-score for her BMD spine was -1.8 and 
the z-score for the TBLH BMD was -1.7. Because of the small number of subjects, 
especially since only one of them was on warfarin at the time the fracture occurred, no 
statistical analysis was conducted to evaluate the effect of warfarin intake on bone fracture in 
our cohort.
Eighteen (69%) patients had a single right ventricular physiology. The remaining 8 (31%) 
had either single left or mixed ventricular morphology.
Twenty five patients had had the Fontan procedures prior to the time of their DXA. One 
patient was at the hemi-Fontan stage. Of the twenty five patients who had their palliation 
completed, 7 had an extracardiac type repair while 18 had a lateral caval (LC) Fontan. All 
but one patient with a LC palliation had a fenestration at the time of the Fontan ranging from 
2.5 – 4 mm in size. Sixteen patients were found to have O2 saturation ≥ 92% by pulse 
oximetry. Sixteen patients had received warfarin for more than 18 months. At the time of 
DXA, 14 subjects were still on warfarin. Although use of warfarin was at the cardiologist's 
discretion, the most common indication for warfarin was the presence of a fenestration (n = 
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11). All were on aspirin 81 mg daily. Table 2 compares the patients who are on warfarin and 
those who are not, taking into account various parameters. There was a trend toward a 
difference between groups in age (p=0.059), and significant differences between groups in z-
scores for weight and BMI.
A spine DXA was obtained on all subjects. DXA of the TBLH was done on 24 patients. The 
mean z-score for BMD spine in all our SV patients was -1.0 ± 0.2 (p<0.0001). (Figure 1) 
This result was also significant when adjusting for height: the mean z-score for BMD spine 
was -0.8 ± 0.3 (p=0.004). Similarly the mean z-score for TBLH BMD in all our SV patients 
was -0.8 ± 0.2 (p<0.0001). This result was also significant when adjusting for height with 
the mean z-score for BMD TBLH -0.5 ± 0.2 (p=0.004).
Subjects on warfarin tended to have lower BMD at both the spine and TBLH than those who 
were not, with a z-score difference of 0.6 ± 0.5 at the spine (p = 0.106) and a difference of 
0.4 ± 0.3 for TBLH (p = 0.132). (Figure 2) After adjusting for activity level, Fontan type, 
oxygen saturation, and height, we still found spine BMD tended to be lower (z-score 
differences of 0.5 ± 0.4, 0.5 ± 0.4, 0.7 ± 0.4, 0.5 ± 0.5, respectively) among patients 
receiving warfarin compared to those who were not on warfarin, although not statistically 
significant (p = 0.134, p = 0.142, p = 0.072, p = 0.132, respectively). (Table 3)
Because of the differences found in table 2, we compared the z- score for BMD spine and 
the z-score for BMD TBLH in patients on and off warfarin, sequentially adjusting for 
weight, z-score of weight, BMI, z-score of BMI and age. Adjustment for these variables did 
not significantly change the trends seen in the above models.
When comparing BMD of patients based on their functional single ventricle, we found that 
patients with single right ventricle also tended to have lower BMD than those patients with 
single left or mixed ventricular morphology. The mean difference in z-score for BMD TBLH 
was 0.6 ± 0.4 (p = 0.055). After adjusting for warfarin, activity level, Fontan type, oxygen 
saturation, and height in these patients we found similar trends with mean z-score 
differences of 0.6 ± 0.4, 0.6 ± 0.4, 0.4 ± 0.4, 0.5 ± 0.5, 0.4 ± 0.3, respectively (p = 0.064, p = 
0.055, p = 0.122, p = 0.158, p = 0.152, respectively). (Table 3)
Discussion
Oral anticoagulants exert their effect by inhibiting vitamin K reductase and vitamin K 
epoxide reductase in the liver and bones, leading to vitamin K deficiency in these organ 
systems. Vitamin K is an essential cofactor for the vitamin K-dependent carboxylase. In the 
bone, through the effect of the vitamin K-dependent carboxylase, vitamin K is responsible 
for the posttranslational modification of three bone matrix components: osteocalcin, matrix 
Gla protein, and protein-S.[36] Matrix Gla protein has been shown to promote endochondral 
calcification. Vitamin K is also important for osteoblast differentiation. Hence by causing 
vitamin K deficiency, warfarin leads to decreased bone mineralization.
Many studies suggest that long-term oral anticoagulation therapy with vitamin K antagonists 
might be associated with a modest increase in osteoporotic fracture risk.[30] This may be 
due to decreases in bone formation. Childhood is a critical period of bone mineral 
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acquisition. Adequate accrual of bone mass is important for preventing fractures in children 
and osteoporosis in adults.[37-38] Therefore, therapies that adversely affect bone mineral 
accrual will have particularly severe effects in pediatric populations. Studies that examine 
the effects of warfarin on BMD in children are very limited. One study enrolled 23 children 
between 5 and 18 years of age who were on warfarin for various reasons, cardiac and 
noncardiac. The conclusion was that long-term use of warfarin may cause low BMD for age 
and sex.[31] A second report of seventeen patients with a mean age 14.7 years (range 8.6 to 
18.8 years) with various cardiac diseases on warfarin for a mean of 8.2 years (range 1-14 
years) showed a reduction in lumbar spine bone mineral apparent density and z-scores 
compared to controls.[32] Of note, however, the children in the treated group, although 
height- and weight-equivalent to the controls, were older and no attempt was made to control 
for puberty, which greatly influences BMD at these ages. In addition neither study compared 
BMD of patients on warfarin with a specific medical condition to patients with the same 
condition but who are not taking warfarin. Rather the comparison was done to normative 
data for BMD; hence it is difficult to conclude whether the effect seen is related to the 
warfarin or to the medical condition for which these patients are on warfarin.
Our study demonstrates that children with SV have decreased BMD compared to the normal 
population even after palliative repair of their congenital heart disease. Because patients post 
Fontan surgery are shorter and BMD is height-dependent,[8] we adjusted our data to height 
and the results were very similar. To our knowledge, this is the first report that highlights this 
important finding.
Another interesting finding is that subjects with single left or mixed ventricular morphology 
tend to have a higher BMD than those patients with single right ventricle even after 
adjusting for variables including warfarin intake. It is difficult to give a clear explanation for 
our finding. However, patients with left single ventricle fare better than patients with a single 
right ventricle as the left ventricle can better sustain the systemic pressure than the right 
ventricle and hence, is less likely to fail.[39] Our speculation is that it is the fact that these 
patients do better in general that leads to better BMD.
As survival after the Fontan procedure continues to improve and the Fontan population 
continues to grow older, recognizing low bone mass early on and initiating early therapy 
when necessary will minimize the risk of subsequent bone fractures. In our center, we 
referred patients who were found to have a BMD z-score below -2 to pediatric 
endocrinology for evaluation. Therapy was instituted in the form of lifestyle and dietary 
changes by encouraging exercise and increasing vitamin D and calcium intake. Because of 
their young age and the potential for bone growth during puberty, no medications were 
started. These patients will be followed up by the endocrinologists yearly and repeat DXA 
scan will be performed at their discretion.
As the efficacy of warfarin in reducing TE after the Fontan procedure continues to be 
controversial,[19-26] avoiding potential side effects of this medication might be a decisive 
factor in limiting its use. Significant risk of bleeding is well established in Fontan patients on 
warfarin.[22,26,40] In our study, the effects of warfarin on BMD were not conclusive. 
However, although not statistically significant, our results show a trend for decrease BMD in 
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patients who are on chronic warfarin even after adjusting for activity level, Fontan type, 
oxygen saturation and height.
Interpretation of our results is subject to certain limitations. Because of the small number of 
patients that could be enrolled in one year, our finding that warfarin decreases BMD did not 
reach statistical significance. Furthermore therapy with either warfarin and aspirin or aspirin 
alone was not randomized but rather left at the cardiologist's discretion. Except for the 
presence of a fenestration, we did not find any other indication to start warfarin. Therefore 
the two groups of patients, the one taking warfarin and the one not taking should be very 
similar except for a slight difference in O2 saturation. This was not shown to have any effect 
on BMD when we adjusted our results for O2 saturation.
In conclusion, our study is the first to show that BMD is significantly reduced in patients 
with SV compared to age and sex matched norms. It is also the first in the pediatric age 
group to compare the effect of warfarin on BMD within a very similar patient population 
particularly, and most importantly, in regards to the medical condition for which warfarin is 
prescribed. Warfarin appears to lower BMD but the effect is less conclusive. Having a 
functional single right ventricle also appears to predispose these patients to decreased BMD 
compared to having a functional left ventricle. Based on our data, we recommend 
performing DXA scan in patients with SV, and particularly those on warfarin and/or single 
right ventricle, at some point before puberty to identify patients with low BMD and hence 
avoid a potential risk of bone fracture in early adulthood. Continued enrollment and further 
study are recommended to better elucidate the effects of warfarin on BMD. Finally, the 
evaluation of other cardiac patients in general and those taking warfarin in particular should 
also be considered.
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Fig. 1. 
Comparison of mean z-score BMD in SV patients and normal population.
a. The mean z-score for BMD spine in SV patients was -1.0 ± 0.2; b. the mean z-score for 
BMD TBLH in the same population was -0.8 ± 0.2. The broken, lines on both diagrams 
represent the mean z-score BMD in our population compared to the mean in the normal 
population in full, black, line. *P < 0.0001
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Fig 2. 
Comparison of mean z-score BMD for patients who were on warfarin and those who were 
not.
Subjects on warfarin tended to have lower BMD at both the spine and TBLH than those who 
were not with a z-score difference of 0.6 ± 0.5 at the spine (p = 0.106) and a difference of 
0.4 ± 0.3 for TBLH (p = 0.132). The purple bar refers to warfarin treatment whereas the blue 
bar indicates no warfarin treatment. Data are presented as mean ± SD
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Table 1
Demographic and cardiac characteristics of the cohort
Demographic/Cardiac Characteristics Sample size n (%)
No. of participants 26
Gender
 Male 13 (50%)
 Female 13 (50%)
Ethnicity
 Caucasian 23 (88%)
 African American 2 (8%)
 Chinese 1 (4%)
Cardiac anatomy
 RV 18 (69%)
 LV 8 (31%)
Surgical palliation stage and type
 Fontan 25 (96%)
  Extracardiac 7 (28%)
  Lateral caval 18 (72%)
   Fenestrated 17 (94%)
   Non fenestrated 1 (6%)
 Hemi-Fontan 1 (4%)
Warfarin
 Yes 16 (62%)
 No 10 (38%)
Aspirin
 Yes 26 (100%)
 No 0 (0%)
O2 saturation
 > 92% 16 (62%)
 < 92% 10 (38%)
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Table 2
Comparison of the patients who were on warfarin and those who were not.
Warfarin (16 pts) No warfarin (10 pts) p value
Male n (%) 7 (44%) 6 (60%) NS
Caucasian n (%) 14 (88%) 8 (80%) NS
Feeding problems n (%) 3 (19%) 1 (10%) NS
HLHS n (%) 11 (69%) 7 (70) NS
Lateral caval Fontan n (%) 11 (69%) 8 (80%) NS
Fenestration n (%) 11 (69%) 7 (70%) NS
Oxygen saturation (%) 92.3 92.8 NS
Age at time of DXA (years) 8.9 7.5 0.059
Height at time of DXA (cm) 126 120 NS
Z-score height -1.17 -0.83 NS
Weight at time of DXA (kg) 26.1 24.9 NS
Z-score weight -1.16 -0.06 0.0146
BMI (kg/m2) 15.9 17.2 NS
Z-score BMI -0.52 0.6 0.0045
Calcium intake (mg) 1188 1476 NS
Activity (activity units) 2.5 2.5 NS
BMI = body mass index; DXA = dual energy x-ray absorptiometry; HLHS = hypoplastic left heart syndrome; NS = nonsignificant; Pts = patients.
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